- Advertise
- OLE Scientific Interchange Workshops
- About OncLive
- Editorial Board
- CureToday.com
- TargetedOnc.com
- CancerNetwork.com
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
Yale Cancer Center | Strategic Alliance Partners
Yale Cancer Center (YCC) is one of only 51 National Cancer Institute-designated comprehensive cancer centers in the nation and the only such center in Connecticut. Cancer treatment for patients is available at Smilow Cancer Hospital through 13 multidisciplinary teams and at 15 Smilow Cancer Hospital Care Centers in Connecticut and Rhode Island. Comprehensive cancer centers play a vital role in the advancement of the NCI’s goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.
Latest from Yale Cancer Center
Dr. Goldberg on the Toxicity Profile of Amivantamab in Metastatic EGFR Exon 20–Mutant NSCLC
March 02, 2021
Video
Sarah B. Goldberg, MD, MPH, discusses the toxicity profile associated with amivantamab in metastatic non–small cell lung cancer that harbors EGFR exon 20 insertion mutations.
Maryam Lustberg Named Director of The Breast Center at Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center
February 26, 2021
Article
Maryam Lustberg, MD, MPH, has been appointed Director of The Breast Center at Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center.
Edward Kaftan Named Assistant Cancer Center Director for Translational Science at Yale Cancer Center
February 25, 2021
Article
Edward Kaftan, PhD, has been appointed Assistant Cancer Center Director for Translational Science at Yale Cancer Center.
Yale Cancer Center Study Shows Targeted Therapy Improves Survival for Advanced Bladder Cancer
February 24, 2021
Article
Enfortumab vedotin significantly prolonged survival as compared with standard chemotherapy in patients with locally advanced or metastatic urothelial carcinoma or bladder cancer, who had previously received platinum-based treatment and a PD-1–PD-L1 inhibitor.
Anne Chiang Appointed Deputy Chief Medical Officer and Chief Integration Officer at Smilow Cancer Hospital
February 23, 2021
Article
Anne Chiang, MD, PhD, has been named Deputy Chief Medical Officer and Chief Integration Officer at Smilow Cancer Hospital.
Dr. Rachel Greenup Appointed Chief of Breast Surgical Oncology at Yale
January 25, 2021
Article
January 25, 2021 - Rachel Adams Greenup, MD, MPH, FACS, has been appointed as Associate Professor of Surgery and Section Chief of Breast Surgery for the Department of Surgery at Yale School of Medicine.